News | Published: Monday, February 3, 2025 12:00 pm
MedAxiom and HealthTech Arkansas have launched year four of HeartX, a cardiovascular-focused healthcare accelerator that facilitates guaranteed hospital pilot projects and clinical trials for accomplished, early-stage companies bringing new cardiovascular innovations to the market.
Applications for the 2025 HeartX cohort are open through April 30, and five companies will be selected in September 2025. The program is seeking companies in three categories: digital health and software, medical devices, and diagnostic platforms. Each company will receive $150,000 of investment capital and is guaranteed at least one pilot project or clinical study with cardiology practices in Arkansas and around the country.
“The HeartX program exemplifies our commitment to bridging the gap between promising cardiovascular innovations and real-world clinical validation,” said Jeff Stinson, director of HealthTech Arkansas. “By guaranteeing early-stage companies direct access to leading cardiology practices for pilots and clinical trials, we’re enabling these innovators to rapidly demonstrate impact, refine their solutions, and ultimately improve patient outcomes. We’re proud to collaborate with MedAxiom again to bring transformative technologies to market.”
“The HeartX accelerator provides young companies with what they need most - access,” said Joe Sasson, PhD, MedAxiom’s chief commercial officer and executive vice president of Ventures. “Participating in HeartX provides funding, exposure, and commercialization support, helping to reach dozens of cardiovascular programs looking for solutions to improve care delivery. We’re confident that this year’s applicants will consist of the best cardiovascular innovations globally, and we encourage all companies focused on improving cardiovascular care to apply.”
HealthTech Arkansas is in its eighth year of administering accelerator programs focused exclusively on provider engagement with early-stage companies, and is now in its fourth year of partnering with MedAxiom on HeartX.
The 2025 HeartX program kick-off will take place during CV Transforum Fall’25, Oct. 16 – 18 in Austin, TX.
More information can be found at HeartXaccelerator.com.
Caristo, England, UK
Caristo Diagnostics CaRi-Heart® technology is the world's only solution to detect and quantify hidden coronary inflammation – a key driver of heart attacks – and quantify coronary plaque from routine coronary CT angiography scans. The CaRi-Heart analysis can predict an individual's risk of cardiac mortality up to 10 years in advance, even before traditional markers of coronary artery disease are detectable. This allows clinicians to intervene earlier with tailored and effective therapy, helping to prevent heart attacks. Learn more at Caristo.com.
Haermonics, The Netherlands
Haermonics uses patented, proven technology born from the need for simple yet effective solutions to address bleeding-related post-operative challenges. By preventively flushing the pericardial cavity, Haermonics Pure significantly reduces bleeding-related reinterventions, complications, and blood transfusions after cardiac surgery. Haermonics Pure continuously monitors novel critical patient parameters, providing real-time insights to clinicians and enabling timely, informed decision-making. Recognizing the innovation's importance, the FDA has granted Haermonics Pure a Breakthrough designation, ensuring faster access for patients in need. Learn more at Haermonics.com.
MultiplAI Health, Maryland, USA
MultiplAI Health is advancing precision diagnostics with an RNA-based blood test powered by artificial intelligence (AI) to detect subclinical cardiovascular diseases. Using genomic sequencing and AI models, the test delivers cardiologists actionable insights for early detection of atherosclerosis and fatty liver disease. It outperforms current cardiovascular disease risk calculators by up to 35% and will soon be available in the US as a CLIA/CAP-approved test. Learn more at MultiplAIHealth.com and Superbiomarker.com.
Peerbridge Health, Tennessee, USA
Peerbridge redefines the diagnostic potential of ambulatory cardiac monitoring. Developed alongside top physicians, the Cor is a unique ambulatory ECG monitor that combines best-in-class signal fidelity with explainable AI to detect heart failure, determine ejection fraction, diagnose sleep apnea, and identify 31 arrhythmias. Merging medical innovation with operational efficiency, Peerbridge delivers unique clinical utility at a fraction of the cost of current monitors. The Cor is approved for reimbursement under standard ECG codes, streamlining adoption for medical institutions. Learn more at PeerbridgeHealth.com.
By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.
